Presentations Include 12-Month Outcomes from the SELUTION4ISR Trial and the SELUTION DeNovo Trial in Coronary Lesions, Alongside Analyses on How Procedural Experience Influences Treatment Strategy ...
Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) 1 for use in Japan. This press ...
GENEVA, May 30, 2022 /PRNewswire/ -- The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent ...
Cordis, a global leader in interventional cardiovascular technologies, announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon for use in Japan. SELUTION SLR™ DEB is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results